LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
LifeMD, Inc. (LFMD)
Company Research
Source: GlobeNewswire
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that it is now offering Foundayo™ (orforglipron) to eligible patients through its weight management program. Foundayo, developed by Eli Lilly and Company, is a once daily oral treatment for adults with obesity or overweight with weight-related medical problems. Foundayo is available to eligible LifeMD patients through the Company’s integration with LillyDirect®, which enables prescriptions to be fulfilled and shipped directly to patients. The starting self-pay price for Foundayo is $149 per month for the initial dosage. Patients with eligible commercial insurance may pay as little as $25 per month through a Lilly savings card, and Medicare coverage is anticipated to begin July 2026. The FDA approved Foundayo on April 1, 2026, making it the second oral GLP-1 therapy approved for weight management. “The approval of Foundayo is another landmar
Show less
Read more
Impact Snapshot
Event Time:
LFMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LFMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LFMD alerts
High impacting LifeMD, Inc. news events
Weekly update
A roundup of the hottest topics
LFMD
News
- LifeMD to Report First Quarter 2026 Financial Results on May 6GlobeNewswire
- How The LifeMD (LFMD) Story Is Shifting Around GLP-1 Growth Plans And 2026 Expectations [Yahoo! Finance]Yahoo! Finance
- LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription ProgramGlobeNewswire
- Novo to sell Wegovy subscriptions on Hims, LifeMD, and others [Seeking Alpha]Seeking Alpha
- LifeMD: Comparing The High Yield Preferred Stock To An Options Income Strategy [Seeking Alpha]Seeking Alpha
LFMD
Earnings
- 3/9/26 - Beat
LFMD
Sec Filings
- 4/1/26 - Form 4
- 4/1/26 - Form 3
- 4/1/26 - Form 3
- LFMD's page on the SEC website